Margaret Olinger - 27 Dec 2023 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Reporting relationship: Chief Commercial Officer
Issuer ticker: AMLX
Reported as of: 27 Dec 2023
Net transaction value: +$9,250
SEC form: 4
Accepted by SEC: 29 Dec 2023, 16:07:35 UTC
Prior SEC filing: 14 Jul 2023
Source filing: View source filing
Reporting owner signature: /s/ Joshua B. Cohen, as Attorney in Fact

Key filing fact

Margaret Olinger filed Form 4 for Amylyx Pharmaceuticals, Inc. (AMLX) on 29 Dec 2023.

Key facts

This page summarizes Margaret Olinger's Form 4 filing for Amylyx Pharmaceuticals, Inc. (AMLX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 29 Dec 2023, 16:07.

Change

Previous filing in this sequence was filed on 14 Jul 2023.
Current net transaction value: +$9,250.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMLX transaction

Common Stock

Options Exercise

Transaction value: $9,250
Shares: +25,000
Change %: +10%
Price: $0.3700^*
Shares after: 276,108
Date: 27 Dec 2023
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AMLX transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -25,000
Change %: -36%
Price: $0.000000
Shares after: 44,577
Date: 27 Dec 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $0.3700
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option are fully vested and exercisable.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .